This online, interactive tool allows users to see how differences in patient uptake and U.S. health care system capacity could affect the delivery of Alzheimer's disease–modifying therapies (DMTs) at the national and state levels from 2025 through 2044, including potential wait times and the number of patients treated. In the model used in this tool, patients move through detection, diagnosis, and treatment phases based on the assumed uptake and health care system capacity for each clinical activity, and patients move through disease states based on transition probabilities from the literature.
The tool expands and updates prior work by examining the role of primary care and geographic variation in capacity across the United States. The simulation results in this tool are not meant to predict what will actually happen with treatment delivery in the future, which will also depend on coverage and reimbursement decisions. Rather, the simulation results illustrate a selected set of possible scenarios to demonstrate the relative impact of varying patient uptake and capacity and how these factors interact to influence the delivery of Alzheimer's DMTs.
This research was sponsored by Genentech and conducted within the Access and Delivery Program of RAND Health Care.
This report is part of the RAND tool series. RAND tools may include models, databases, calculators, computer code, GIS mapping tools, practitioner guidelines, web applications, and various toolkits. All RAND tools undergo rigorous peer review to ensure both high data standards and appropriate methodology in keeping with RAND's commitment to quality and objectivity.
Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.